NDA 211158 · Amneal
Tigecycline
Tigecycline · Intravenous · Tetracycline-class Antibacterial
Last checked: Nov 19, 2026Latest source record: Mar 31, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Aug 2, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
64
23 Phase 3, 6 recruiting
FAERS reports
4,358
4,073 serious, 1,192 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ALL-CAUSE MORTALITY An increase in all-cause mortality has been observed in a meta-analysis of Phase 3 and 4 clinical trials in tigecycline for injection-treated patients versus comparator. The cause of this mortality risk difference of 0.6% (95% CI 0.1, 1.2) has not been established. Tigecycline for injection should be reserved for use in situations when alternative treatments are not suitable [see Indications and Usage (1.4) , Warnings and Precautions (5.1 , 5.2) and Adverse Reactions (6.1) ]. WARNING: ALL-CAUSE MORTALITY See full prescribing information for complete boxed warning. All-cause mortality was higher in patients treated with tigecycline for injection than comparators in a meta-analysis of clinical trials. The cause of this mortality risk difference of 0.6% (95% CI 0.1, 1.2) has not been established. Tigecycline for injection should be reserved for use in...
What it is approved for
From the label in effect Dec 17, 2024.
Tigecycline is a tetracycline class antibacterial indicated in patients 18 years of age and older for: Complicated skin and skin structure infections (1.1) Complicated intra-abdominal infections (1.2) Community-acquired bacterial pneumonia (1.3) Limitations of Use: Tigecycline for injection is not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilator-associated pneumonia. (1.4) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tigecycline for injection and other antibacterial drugs, tigecycline for injection should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. (1.5) 1.1 Complicated Skin and Skin Structure Infections Tigecycline for injection is indicated in patients 18 years of age and older for the treatment of complicated skin and skin structure infections caused by susceptible isolates of Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus ), Streptococcus pyogenes, Enterobacter cloacae, Klebsiella pneumoniae, and Bacteroides fragilis. 1.2 Complicated Intra-abdominal Infections Tigecycline for injection is indicated in patients 18 years of age and older for the treatment of complicated intra-abdominal infections caused by susceptible isolates of Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus anginosus grp. (includes S....
Mechanism: Tigecycline is a tetracycline class antibacterial drug [see Microbiology (12.4) ].
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- TIGECYCLINE · TIGECYCLINE 50MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Tigecycline" as an intervention, any sponsor and status, largest first.
- The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) TrialPivotal-lookingCompleted
University of WashingtonAcademic, hospital or other
NCT02800785 · 1,552 participants · Start May 2016 · Primary completion Mar 5, 2020
Drug: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin · For: Appendicitis
Sites: Sylmar, California; Torrance, California; Aurora, Colorado · 25 sites in all
- Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.Pivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00366249 · 1,061 participants · Start Jan 2007 · Primary completion Mar 2009
Drug: Tigecycline; Ertapenem · For: Bacterial Infections; Diabetic Foot; Osteomyelitis
Sites: Los Angeles, California; Northridge, California; San Francisco, California · 211 sites in all
- Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized SubjectsPivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00081744 · 850 participants · Start Nov 2002 · Primary completion Aug 2004
Drug: Tigecycline · For: Gram-Positive Bacterial Infections; Cross Infection
- Optimising TREATment for Severe Gram-Negative Bacterial InfectionsPivotal-lookingRecruiting
National University of SingaporeAcademic, hospital or other
NCT07004049 · 600 participants (planned) · Start Apr 21, 2025 · Primary completion Dec 31, 2028
Drug: Colistin/Polymyxin B + Sulbactam; Colistin/Polymyxin B + Tigecycline/Eravacycline and 12 more · For: Bloodstream Infection; Ventilator Associated Bacterial Pneumonia; Hospital Acquired Bacterial Pneumonia and 2 more
Sites: Brisbane, Australia; Hangzhou, China; Xi'an, China · 41 sites in all
- Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin InfectionsPivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00368537 · 550 participants · Start Sep 2006 · Primary completion Sep 2008
Drug: Tigecycline; ampicillin-sulbactam · For: Skin Diseases, Bacterial
Sites: Scottsdale, Arizona; Jonesboro, Arkansas; Chula Vista, California · 57 sites in all
- Study Comparing Tigecycline and Vancomycin With Aztreonam in Complicated Skin and Skin Structure InfectionsPivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00228410 · 503 participants · Start Nov 2002 · Primary completion Dec 2003
Drug: Tigecycline; vancomycin with aztreonam · For: Skin Diseases, Infectious
- Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)Pivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00230971 · 473 participants · Start Oct 2005 · Primary completion Sep 2008
Drug: tigecycline; ceftriaxone plus metronidazole · For: Appendicitis; Cholecystitis; Diverticulitis and 3 more
Sites: Nambour, Australia; Cairns, Australia; Parkville, Australia · 68 sites in all
- A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal InfectionPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01721408 · 470 participants · Start Nov 2012 · Primary completion Oct 2015
Drug: Tigecycline; Imipenem/cilastatin · For: Intra-abdominal Infection
Sites: Anqing, China; Xicheng District, China; Xiamen, China · 47 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective638
- off label use549
- nausea302
- drug resistance213
- sepsis207
- vomiting205
- septic shock193
- thrombocytopenia193
- pathogen resistance172
- product use in unapproved indication168
- diarrhoea156
- acute kidney injury153
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 8 |
| 2007 | 31 |
| 2008 | 63 |
| 2009 | 50 |
| 2010 | 37 |
| 2011 | 61 |
| 2012 | 71 |
| 2013 | 80 |
| 2014 | 79 |
| 2015 | 151 |
| 2016 | 107 |
| 2017 | 216 |
| 2018 | 241 |
| 2019 | 404 |
| 2020 | 360 |
| 2021 | 419 |
| 2022 | 332 |
| 2023 | 417 |
| 2024 | 518 |
| 2025 | 413 |
| 2026 | 298 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tigecycline (Tigecycline)
2024 spending
$2.4M
Beneficiaries
652
3,241 claims
Per beneficiary
$3,715
$19.85 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,402,277 |
| 2021 | $3,640,666 |
| 2022 | $2,858,482 |
| 2023 | $3,491,734 |
| 2024 | $2,422,416 |
Part B: Tigecycline* (Tigecycline*) · HCPCS J3243
2024 spending
$40K
Beneficiaries
41
614 claims
Per beneficiary
$967
2024 ASP limit $0.63 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $510,008 |
| 2021 | $318,211 |
| 2022 | $80,981 |
| 2023 | $48,843 |
| 2024 | $39,666 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Global status of antimicrobial resistance in clinical Enterococcus faecalis isolates: systematic review and meta-analysis.
Guan L, Beig M, Wang L, et al. · Ann Clin Microbiol Antimicrob 2024 · Systematic Review, Meta-Analysis
- The effect of antibiotics on the composition of the intestinal microbiota - a systematic review.
Zimmermann P, Curtis N · J Infect 2019 · Research Support, Non-U.S. Gov't, Systematic Review
- Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
Kong W, Deng T, Li S, et al. · BMC Infect Dis 2023 · Systematic Review, Network Meta-Analysis
- Comparative effectiveness and safety of six antibiotics in treating MRSA infections: A network meta-analysis.
Ju G, Zhang Y, Ye C, et al. · Int J Infect Dis 2024 · Comparative Study, Network Meta-Analysis
- Antibiotics for ventilator-associated pneumonia.
Arthur LE, Kizor RS, Selim AG, et al. · Cochrane Database Syst Rev 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- MRSA: treating people with infection.
Nathwani D, Davey PG, Marwick CA · BMJ Clin Evid 2010 · Systematic Review
Sponsor: Amneal
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.